Braveheart Bio (NASDAQ:BRVE) Upgraded by The Goldman Sachs Group to Strong-Buy Rating

The Goldman Sachs Group upgraded shares of Braveheart Bio (NASDAQ:BRVE) to a strong-buy rating in a research note released on Monday morning,Zacks reports.

Other research analysts also recently issued reports about the stock. Cantor Fitzgerald initiated coverage on shares of Braveheart Bio in a research report on Monday. They issued an “overweight” rating and a $40.00 price target on the stock. Wall Street Zen raised shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. TD Cowen began coverage on shares of Braveheart Bio in a research report on Monday. They set a “buy” rating for the company. Stifel Nicolaus assumed coverage on shares of Braveheart Bio in a research note on Monday. They set a “buy” rating and a $45.00 price objective on the stock. Finally, Jefferies Financial Group started coverage on shares of Braveheart Bio in a report on Monday. They issued a “buy” rating and a $48.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $45.25.

Braveheart Bio Trading Down 7.1%

Shares of BRVE opened at $25.50 on Monday. Braveheart Bio has a 12-month low of $24.31 and a 12-month high of $32.00.

Insider Buying and Selling at Braveheart Bio

In other news, Director Erez Chimovits bought 1,940,000 shares of Braveheart Bio stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the purchase, the director directly owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This trade represents a 19.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Growth Opportunities F. Forbion bought 1,920,000 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was purchased at an average price of $18.00 per share, with a total value of $34,560,000.00. Following the transaction, the insider owned 11,640,546 shares in the company, valued at $209,529,828. The trade was a 19.75% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 8,751,942 shares of company stock valued at $157,534,956.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.